secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016251
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation
--------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.
- Net loss $24.9M ($0.28/share) vs $4.5M ($0.09) in Q2 2021; R&D expense $23.7M vs $19.1M.
- TNG908 Phase 1/2 enrolling MTAP-deleted solid tumors; FDA Orphan Drug Designation for MPNST.
- TNG462 (45-fold more potent PRMT5 inhibitor) and TNG260 declared development candidates; IND filings expected 1H 2023.
- Added to Russell 2000, 3000 and Microcap indexes in June 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/0000950170-22-016251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer